tetano
Editor, Senior Moderator
Adv Healthc Mater
. 2024 Feb 27:e2304188.
doi: 10.1002/adhm.202304188. Online ahead of print. Intranasal Epitope-Polymer Vaccine Lodges Resident Memory T Cells Protecting against Influenza Virus
Ziyang Liu[SUP] 1 [/SUP], Md Tanvir Kabir[SUP] 2 [/SUP], Shuxiong Chen[SUP] 2 [/SUP], Heran Zhang[SUP] 1 [/SUP], Linda M Wakim[SUP] 1 [/SUP], Bernd H A Rehm[SUP] 2 3 [/SUP]
Affiliations
Intranasal vaccines, unlike injectable vaccines, boost immunity along the respiratory tract; this can significantly limit respiratory virus replication and shedding. There remains a need to develop mucosal adjuvants and vaccine delivery systems that are both safe and effective following intranasal administration. Here, we have bioengineered biopolymer particles (BP) densely coated with repeats of MHC class I restricted immunodominant epitopes derived from influenza A virus namely NP[SUB]366[/SUB] , a nucleoprotein-derived epitope and PA[SUB]224[/SUB] , a polymerase acidic subunit derived epitope. These BP-NP[SUB]366[/SUB] /PA[SUB]224[/SUB] could be manufactured at high yield and are obtained at ∼93% purity exhibiting ambient-temperature stability. Immunological characterisation includes comparing systemic and mucosal immune responses mounted following intramuscular or intranasal immunisation. Immunization with BP-NP[SUB]366[/SUB] /PA[SUB]224[/SUB] without adjuvant triggers influenza-specific CD8[SUP]+[/SUP] T cell priming and memory CD8[SUP]+[/SUP] T cell development. Co-delivery with the adjuvant poly(I:C) significantly boosts the size and functionality of the influenza-specific pulmonary resident memory CD8[SUP]+[/SUP] T cell pool. Intranasal, but not intramuscular delivery of BP-NP[SUB]366[/SUB] /PA[SUB]224[/SUB] with poly(I:C) provides protection against influenza virus challenge. Overall, the BP approach demonstrates as a suitable antigen formulation for intranasal delivery toward induction of systemic protective T cell responses against influenza virus. This article is protected by copyright. All rights reserved.
Keywords: influenza; intranasal delivery; polyhydroxybutyrate; resident memory T cells; subunit vaccine; vaccine.
. 2024 Feb 27:e2304188.
doi: 10.1002/adhm.202304188. Online ahead of print. Intranasal Epitope-Polymer Vaccine Lodges Resident Memory T Cells Protecting against Influenza Virus
Ziyang Liu[SUP] 1 [/SUP], Md Tanvir Kabir[SUP] 2 [/SUP], Shuxiong Chen[SUP] 2 [/SUP], Heran Zhang[SUP] 1 [/SUP], Linda M Wakim[SUP] 1 [/SUP], Bernd H A Rehm[SUP] 2 3 [/SUP]
Affiliations
- PMID: 38411375
- DOI: 10.1002/adhm.202304188
Intranasal vaccines, unlike injectable vaccines, boost immunity along the respiratory tract; this can significantly limit respiratory virus replication and shedding. There remains a need to develop mucosal adjuvants and vaccine delivery systems that are both safe and effective following intranasal administration. Here, we have bioengineered biopolymer particles (BP) densely coated with repeats of MHC class I restricted immunodominant epitopes derived from influenza A virus namely NP[SUB]366[/SUB] , a nucleoprotein-derived epitope and PA[SUB]224[/SUB] , a polymerase acidic subunit derived epitope. These BP-NP[SUB]366[/SUB] /PA[SUB]224[/SUB] could be manufactured at high yield and are obtained at ∼93% purity exhibiting ambient-temperature stability. Immunological characterisation includes comparing systemic and mucosal immune responses mounted following intramuscular or intranasal immunisation. Immunization with BP-NP[SUB]366[/SUB] /PA[SUB]224[/SUB] without adjuvant triggers influenza-specific CD8[SUP]+[/SUP] T cell priming and memory CD8[SUP]+[/SUP] T cell development. Co-delivery with the adjuvant poly(I:C) significantly boosts the size and functionality of the influenza-specific pulmonary resident memory CD8[SUP]+[/SUP] T cell pool. Intranasal, but not intramuscular delivery of BP-NP[SUB]366[/SUB] /PA[SUB]224[/SUB] with poly(I:C) provides protection against influenza virus challenge. Overall, the BP approach demonstrates as a suitable antigen formulation for intranasal delivery toward induction of systemic protective T cell responses against influenza virus. This article is protected by copyright. All rights reserved.
Keywords: influenza; intranasal delivery; polyhydroxybutyrate; resident memory T cells; subunit vaccine; vaccine.